How GLP-1 Works
GLP-1 (Glucagon-Like Peptide-1) is a natural incretin hormone released by the gut after meals. It travels through the body and binds to specific proteins called GLP-1 receptors, which act like cellular switches. These receptors are found in key organs such as the pancreas, brain, liver, heart, bones, and fat tissue.
When GLP-1 receptors are activated, they trigger a cascade of beneficial responses:
What Hummsa Offers?
Hummsa’s lead molecule, HB PK002, is a next-generation, small-molecule GLP-1 receptor agonist. It mimics natural GLP-1 to activate the same therapeutic pathways, but with greater precision and accessibility.
Why Preventive Oral GLP-1 Agonists?
GLP-1 therapies have already transformed diabetes and obesity care. Yet most current treatments focus on symptom management, not the disease root causes.
At Hummsa, we see the future in prevention and regeneration.
Our molecule, HB PK002, is designed not just for ease of use but to slow, stop, or even reverse disease progression before irreversible damage occurs.
HB PK002 overcomes current therapy challenges by offering:
- MASLD/MASH (Fatty Liver Disease): Reduces liver fat and fibrosis, key drivers of disease progression
- Osteoporosis: Enhances bone formation and reduces breakdown, lowering fracture risk
- Alzheimer’s Disease: Provides neuroprotection and reduces inflammation, potentially slowing cognitive decline
.avif)
- Glucose regulation
- Lipid metabolism
- Inflammation
- Neural protection
- Bone health
Hummsa’s pipeline is advancing rapidly through preclinical development, preparing for Investigational New Drug (IND) enabling studies.
Our lead molecule, HB PK002, targets six key indications, all leveraging GLP-1 receptor activation tailored to specific disease biology.
Contact us
Phone
